Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or-independent mechanisms and reduces the efficacy of docetaxel

British Journal of Cancer

Volumn 104, Issue 10, 2011, Pages 1587-1593

  Uzoh, C C ^a,b   Holly, J M P ^a   Biernacka, K M ^a   Persad, R A ^b   Bahl, A ^c   Gillatt, D ^a   Perks, C M ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

Author keywords

b 1 integrin; IGF independent; IGFBP 2; PTEN

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; BETA1 INTEGRIN; DOCETAXEL; INTEGRIN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TRYPAN BLUE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL COUNT; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TAXOIDS; TRANSFECTION;

EID: 79955819896     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.127     Document Type: Article

References (29)

1. Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107: 873-877 (Pubitemid 37429826)
2. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758-1764 (Pubitemid 29518772)
3. Chatterjee S, Park ES, Soloff MS (2004) Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol 11: 876-884 (Pubitemid 39490739)
4. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192 (Pubitemid 43292562)
5. Dahia PL (2000) PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 7: 115-129 (Pubitemid 30609989)
6. Degraff DJ, Aguiar AA, Chen Q, Adams LK, Williams BJ, Sikes RA (2010) Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells. Am J Transl Res 2: 200-208
7. Degraff DJ, Aguiar AA, Sikes RA (2009) Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res 1: 115-130
8. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781
9. Gu J, Tamura M, Yamada KM (1998) Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 143: 1375-1383 (Pubitemid 28559837)
10. Holly J, Perks C (2006) The role of insulin-like growth factor binding proteins. Neuroendocrinology 83: 154-160 (Pubitemid 44578867)
11. Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L (2005) Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol 47: 695-702 (Pubitemid 40521924)
12. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A (1993) Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77: 229-233 (Pubitemid 23206808)
13. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME (2003) Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63: 3575-3584 (Pubitemid 36793038)
14. Kumar CC (1998) Signaling by integrin receptors. Oncogene 17: 1365-1373
15. Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 104: 5563-5568 (Pubitemid 47175720)
16. Meinbach DS, Lokeshwar BL (2006) Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? Urol Oncol 24: 294-306 (Pubitemid 43963416)
17. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P (2003) Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 105: 14-19 (Pubitemid 36418479)
18. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ (1997) Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 33: 263-271
19. Perks CM, Holly JM (2008) IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia 13: 455-469
20. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM (2007) IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26: 5966-5972
21. Pollak M (2008) Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22: 625-638
22. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey Jr JV, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry Jr CP, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-471, W483-468
23. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW (2004) Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32: 859-868 (Pubitemid 38877689)
24. Schwartz MA (1997) Integrins, oncogenes, and anchorage independence. J Cell Biol 139: 575-578 (Pubitemid 27485824)
25. Skogseth H, Follestad T, Larsson E, Halgunset J (2006) Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase. APMIS 114: 364-371 (Pubitemid 43829427)
26. Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM (1999) PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 274: 20693-20703
27. Thomas F, Holly JM, Persad R, Bahl A, Perks CM (2010) Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate 70: 856-865
28. Thomas F, Patel S, Holly JM, Persad R, Bahl A, Perks CM (2009) Dihydrotestosterone sensitises LNCaP cells to death induced by epigallocatechin-3-Gallate (EGCG) or an IGF-I receptor inhibitor. Prostate 69: 219-224
29. Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, Persad RA (2009) PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU Int 104: 556-561